Pub Date : 2020-12-10DOI: 10.37155/2717-5278-0202-1
P. Lissoni, G. Porro, C. Galli, R. Codogni, N. Merli, G. Fede
It is known since more than 50 years that the pineal gland plays a fundamental role in the natural biological resistance against cancer onset and growth. The anticancer role of the pineal gland is due to the production of several antitumor molecules, the most known of them is the indole hormone melatonin (MLT). Unfortunately, although there are a lot of experimental evidences that MLT is completely non-toxic, no oncologist seem to be interested to the clinical use of MLT in the treatment of human neoplasms, at least from a palliative point of view. However, a few number of clinical studies of MLT in the complementary treatment of cancer has demonstrated that the anticancer activity of MLT is a dose-dependent phenomenon. On this basis, a preliminary study with a very high dose of MLT, consisting of 1000 mg/once day in the evening, was carried out in untreatable cancer patients, who failed to respond to the conventional anticancer therapies, and for whom the only available treatment was the palliative therapy. The treatment was well tolerated, and a disease control was achieved in 54% patients. These preliminary results would justify further clinical studies to generate a new interpretation of cancer control, consisting of the pharmacological reproduction of the same mechanisms responsible for the natural resistance against cancer development.
{"title":"A Preliminary Phase-2 Study with very High-Dose of Melatonin (1000 mg/day) in Untreatable Advanced Cancer Patients Already Progression on Previous Palliative Therapy with High-Dose Melatonin","authors":"P. Lissoni, G. Porro, C. Galli, R. Codogni, N. Merli, G. Fede","doi":"10.37155/2717-5278-0202-1","DOIUrl":"https://doi.org/10.37155/2717-5278-0202-1","url":null,"abstract":"It is known since more than 50 years that the pineal gland plays a fundamental role in the natural biological resistance against cancer onset and growth. The anticancer role of the pineal gland is due to the production of several antitumor molecules, the most known of them is the indole hormone melatonin (MLT). Unfortunately, although there are a lot of experimental evidences that MLT is completely non-toxic, no oncologist seem to be interested to the clinical use of MLT in the treatment of human neoplasms, at least from a palliative point of view. However, a few number of clinical studies of MLT in the complementary treatment of cancer has demonstrated that the anticancer activity of MLT is a dose-dependent phenomenon. On this basis, a preliminary study with a very high dose of MLT, consisting of 1000 mg/once day in the evening, was carried out in untreatable cancer patients, who failed to respond to the conventional anticancer therapies, and for whom the only available treatment was the palliative therapy. The treatment was well tolerated, and a disease control was achieved in 54% patients. These preliminary results would justify further clinical studies to generate a new interpretation of cancer control, consisting of the pharmacological reproduction of the same mechanisms responsible for the natural resistance against cancer development.","PeriodicalId":348972,"journal":{"name":"Trends in Oncology","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133875204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-31DOI: 10.37155/2717-5278-0101-3
Zijing Yang
Objective: To clarify the current status of traditional Chinese medicine (TCM) application and research in the field of tumor treatment, and provide reference guidance for the rational application of TCM in the treatment of tumors, multidisciplinary cooperation in tumor treatment, and improvement of TCM education. Methods: From July 2015 to June 2016, the patients in oncology department of four large-scale comprehensive first-class hospitals in China were selected. The general clinical data, clinical application of TCM and cognitive status data of tumor patients were obtained by using electronic medical record database combined with questionnaire to explore the clinical application of TCM in tumor treatment from the perspective of tumor patients. Results: The proportion of patients receiving chemotherapy (including targeted therapy) and TCM treatment was 28.7%. 16.6% of doctors were concerned that TCM combined with chemotherapy might produce adverse reactions. 20.0% of doctors think they have enough knowledge to answer questions related to TCM. 22.0% of doctors have received continuing education in TCM. During the treatment, 36.5% of patients had discussed TCM with their doctors. A total of 44.9% of doctors believe that TCM treatment is effective. Conclusion: The purpose of applying TCM is mainly to regulate the body’s immunity, improve the symptoms such as loss of appetite, fatigue and sleep disorder, increase the effect and reduce toxicity of radiotherapy and chemotherapy. The treatment is mainly based on TCM compounds and proprietary Chinese medicines.
{"title":"A Multi-Center Cross-Sectional Study of the Status of Patient-Oriented Chinese Medicine Treatment of Malignant Tumors","authors":"Zijing Yang","doi":"10.37155/2717-5278-0101-3","DOIUrl":"https://doi.org/10.37155/2717-5278-0101-3","url":null,"abstract":"Objective: To clarify the current status of traditional Chinese medicine (TCM) application and research in the field of tumor treatment, and provide reference guidance for the rational application of TCM in the treatment of tumors, multidisciplinary cooperation in tumor treatment, and improvement of TCM education. Methods: From July 2015 to June 2016, the patients in oncology department of four large-scale comprehensive first-class hospitals in China were selected. The general clinical data, clinical application of TCM and cognitive status data of tumor patients were obtained by using electronic medical record database combined with questionnaire to explore the clinical application of TCM in tumor treatment from the perspective of tumor patients. Results: The proportion of patients receiving chemotherapy (including targeted therapy) and TCM treatment was 28.7%. 16.6% of doctors were concerned that TCM combined with chemotherapy might produce adverse reactions. 20.0% of doctors think they have enough knowledge to answer questions related to TCM. 22.0% of doctors have received continuing education in TCM. During the treatment, 36.5% of patients had discussed TCM with their doctors. A total of 44.9% of doctors believe that TCM treatment is effective. Conclusion: The purpose of applying TCM is mainly to regulate the body’s immunity, improve the symptoms such as loss of appetite, fatigue and sleep disorder, increase the effect and reduce toxicity of radiotherapy and chemotherapy. The treatment is mainly based on TCM compounds and proprietary Chinese medicines.","PeriodicalId":348972,"journal":{"name":"Trends in Oncology","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129174348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-31DOI: 10.37155/2717-5278-0101-5
Man Li
In recent years, malignant tumors have become the number one major disease that seriously endangers health and causes death. The main methods for the treatment of malignant tumors are surgery, radiotherapy and chemotherapy. However, radiation therapy and chemotherapy have the disadvantages of poor specificity and damage to the immune function of the body. Therefore, the preparation of anti-cancer active ingredients with low toxicity and good efficacy can protect and improve the immune function of tumor patients. In particular, it is of great significance to improve the cellular immune function of patients and to reduce the toxic and side effects of radiotherapy and chemotherapy for preventing the occurrence of tumors and improving the therapeutic effect of tumors. A large number of studies have shown that polysaccharides can enhance immune function and anti-tumor effects. Plant polysaccharides from different sources have different mechanisms. Different polysaccharides are formulated into a mixed preparation according to a certain ratio. After entering the body, the anti-tumor and anti-radiation effects of the body will be improved through different approaches, and the mechanism of action will be explored, which will provide important experimental basis for clinical treatment of tumor patients.
{"title":"Study on Antitumor Activity and Mechanism of Compound Polysaccharide","authors":"Man Li","doi":"10.37155/2717-5278-0101-5","DOIUrl":"https://doi.org/10.37155/2717-5278-0101-5","url":null,"abstract":"In recent years, malignant tumors have become the number one major disease that seriously endangers health and causes death. The main methods for the treatment of malignant tumors are surgery, radiotherapy and chemotherapy. However, radiation therapy and chemotherapy have the disadvantages of poor specificity and damage to the immune function of the body. Therefore, the preparation of anti-cancer active ingredients with low toxicity and good efficacy can protect and improve the immune function of tumor patients. In particular, it is of great significance to improve the cellular immune function of patients and to reduce the toxic and side effects of radiotherapy and chemotherapy for preventing the occurrence of tumors and improving the therapeutic effect of tumors. A large number of studies have shown that polysaccharides can enhance immune function and anti-tumor effects. Plant polysaccharides from different sources have different mechanisms. Different polysaccharides are formulated into a mixed preparation according to a certain ratio. After entering the body, the anti-tumor and anti-radiation effects of the body will be improved through different approaches, and the mechanism of action will be explored, which will provide important experimental basis for clinical treatment of tumor patients.","PeriodicalId":348972,"journal":{"name":"Trends in Oncology","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133773533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-31DOI: 10.37155/2717-5278-0101-4
L. Wan, Ye Zhang
Malignant tumors are a key factor that threatens human health. With the continuous development of molecular biology, immunology and oncology, tumor immunodrugs have gradually become an effective means to suppress malignant tumors after surgery, radiotherapy and chemotherapy. The United States, as a leading country in the development of tumor immunodrugs, has rich clinical trial practice experience and comprehensive clinical trial considerations. Therefore, this article intends to explore the progress of clinical trials of tumor immunodrugs in the United States in terms of the alternative endpoints of clinical trials, clinical trials of adolescent tumor patients, and the design of a single clinical trial main plan for multiple drugs and/or multiple tumor subgroups, thereby providing a reference for optimizing the design of clinical trials in China, expanding the application scope of tumor immunodrugs, and speeding up the process of marketing new drugs.
{"title":"Progress in Clinical Trials of Tumor Immunodrugs in the United States","authors":"L. Wan, Ye Zhang","doi":"10.37155/2717-5278-0101-4","DOIUrl":"https://doi.org/10.37155/2717-5278-0101-4","url":null,"abstract":"Malignant tumors are a key factor that threatens human health. With the continuous development of molecular biology, immunology and oncology, tumor immunodrugs have gradually become an effective means to suppress malignant tumors after surgery, radiotherapy and chemotherapy. The United States, as a leading country in the development of tumor immunodrugs, has rich clinical trial practice experience and comprehensive clinical trial considerations. Therefore, this article intends to explore the progress of clinical trials of tumor immunodrugs in the United States in terms of the alternative endpoints of clinical trials, clinical trials of adolescent tumor patients, and the design of a single clinical trial main plan for multiple drugs and/or multiple tumor subgroups, thereby providing a reference for optimizing the design of clinical trials in China, expanding the application scope of tumor immunodrugs, and speeding up the process of marketing new drugs.","PeriodicalId":348972,"journal":{"name":"Trends in Oncology","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133529367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-31DOI: 10.37155/2717-5278-0101-1
Yi Lin
Objective: To evaluate the efficacy and application advantages of traditional Chinese medicine (TCM) for patients with advanced non-small cell lung cancer (NSCLC), and to explore the factors related to the maintenance effect of TCM. Methods: Case data in this study were obtained from the Oncology Wards and Outpatient Clinics of Guang’anmen Hospital, China Academy of Chinese Medical Sciences. According to the inclusion and exclusion criteria, patients with advanced NSCLC meeting the study criteria, who were controlled by first-line chemotherapy, were divided into two groups: the maintenance treatment group and the control group according to whether there was TCM intervention and the degree of intervention. The data and treatment status were recorded through retrospective research, and the patients were followed up to record their survival time. The efficacy of TCM maintenance treatment was evaluated together by the patient’s overall survival time (PFS, OS) and quality of life (syndrome score, Karnofsky performance status, weight); and then relevant factor analysis was carried out. Results: A total of 66 eligible patients were included in the study, including 36 patients in the TCM maintenance treatment group and 30 patients in the control group. There was no significant difference between the two groups in terms of age, gender, smoking status, comorbidities, tumor location, stage, pathological type, complications, chemotherapy cycle and the first-line treatment effect in the baseline data. At the end of the study, it was found that the median progression-free survival (PFS) of the treatment group was 5.6 months, and that of the control group was 3 months. The difference between the two groups was statistically significant (P = 0.014 0.05). In terms of quality of life, compared with the control group, the TCM maintenance treatment group of traditional Chinese medicine can significantly improve the patient’s syndrome score, Karnofsky performance status and weight of the patients. The difference was statistically significant (P < 0.0.5). Through binary logistic stepwise regression analysis, it was found that the PFS and quality of life in TCM maintenance treatment group had obvious correlation with the TCM maintenance treatment mode; that is to say, patients who simultaneously applied oral and intravenous anti-cancer TCM could obtain greater benefits in PFS and quality of life. Conclusion: The use of TCM maintenance treatment can extend the PFS of patients with advanced NSCLC after first-line therapy, and has a tendency to extend the overall survival time. TCM maintenance treatment Can significantly improve patients' symptoms, improve physical condition scores, and weight, thus Improve the quality of life in patients with advanced NSCLC.
{"title":"Study on Traditional Chinese Medicine Maintenance Therapy for Advanced Non-small\u0000Cell Lung Cancer","authors":"Yi Lin","doi":"10.37155/2717-5278-0101-1","DOIUrl":"https://doi.org/10.37155/2717-5278-0101-1","url":null,"abstract":"Objective: To evaluate the efficacy and application advantages of traditional Chinese medicine (TCM) for patients with advanced non-small cell lung cancer (NSCLC), and to explore the factors related to the maintenance effect of TCM. Methods: Case data in this study were obtained from the Oncology Wards and Outpatient Clinics of Guang’anmen Hospital, China Academy of Chinese Medical Sciences. According to the inclusion and exclusion criteria, patients with advanced NSCLC meeting the study criteria, who were controlled by first-line chemotherapy, were divided into two groups: the maintenance treatment group and the control group according to whether there was TCM intervention and the degree of intervention. The data and treatment status were recorded through retrospective research, and the patients were followed up to record their survival time. The efficacy of TCM maintenance treatment was evaluated together by the patient’s overall survival time (PFS, OS) and quality of life (syndrome score, Karnofsky performance status, weight); and then relevant factor analysis was carried out. Results: A total of 66 eligible patients were included in the study, including 36 patients in the TCM maintenance treatment group and 30 patients in the control group. There was no significant difference between the two groups in terms of age, gender, smoking status, comorbidities, tumor location, stage, pathological type, complications, chemotherapy cycle and the first-line treatment effect in the baseline data. At the end of the study, it was found that the median progression-free survival (PFS) of the treatment group was 5.6 months, and that of the control group was 3 months. The difference between the two groups was statistically significant (P = 0.014 0.05). In terms of quality of life, compared with the control group, the TCM maintenance treatment group of traditional Chinese medicine can significantly improve the patient’s syndrome score, Karnofsky performance status and weight of the patients. The difference was statistically significant (P < 0.0.5). Through binary logistic stepwise regression analysis, it was found that the PFS and quality of life in TCM maintenance treatment group had obvious correlation with the TCM maintenance treatment mode; that is to say, patients who simultaneously applied oral and intravenous anti-cancer TCM could obtain greater benefits in PFS and quality of life. Conclusion: The use of TCM maintenance treatment can extend the PFS of patients with advanced NSCLC after first-line therapy, and has a tendency to extend the overall survival time. TCM maintenance treatment Can significantly improve patients' symptoms, improve physical condition scores, and weight, thus Improve the quality of life in patients with advanced NSCLC.","PeriodicalId":348972,"journal":{"name":"Trends in Oncology","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130117881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-31DOI: 10.37155/2717-5278-0101-2
Ye Xu, Zhong-feng Li, M. Meng
Objectives: To evaluate the effect of Xiaoaiping combined with oxaliplatin and capecitabine in the treatment of advanced metastatic gastric adenocarcinoma. Methods: Seventy patients with advanced metastatic gastric adenocarcinoma in our hospital from January 2018 to March 2019 were randomly divided into the control group treated with oxaliplatin and capecitabine chemotherapy and the observation group treated with Xiaoaiping. Each group has 35 cases. The short-term efficacy of the two groups was compared. Results: The total effective rate and disease control rate of the observation group were higher than that of the control group. After treatment, tumor markers, vascular endothelial growth factors and inflammatory cytokines were lower than those in the control group. The quality of life score and peripheral lymphocyte subgroup were higher than the control group. The difference was statistically significant (P 0.05). Conclusions: Xiaoaiping combined with oxaliplatin and capecitabine is effective in the treatment of advanced metastatic gastric adenocarcinoma. It's worth popularizing.
{"title":"Evaluation of Xiaoaiping Combined with Oxaliplatin and Capecitabine in the Treatment\u0000of Advanced Metastatic Gastric Adenocarcinoma","authors":"Ye Xu, Zhong-feng Li, M. Meng","doi":"10.37155/2717-5278-0101-2","DOIUrl":"https://doi.org/10.37155/2717-5278-0101-2","url":null,"abstract":"Objectives: To evaluate the effect of Xiaoaiping combined with oxaliplatin and capecitabine in the treatment of advanced metastatic gastric adenocarcinoma. Methods: Seventy patients with advanced metastatic gastric adenocarcinoma in our hospital from January 2018 to March 2019 were randomly divided into the control group treated with oxaliplatin and capecitabine chemotherapy and the observation group treated with Xiaoaiping. Each group has 35 cases. The short-term efficacy of the two groups was compared. Results: The total effective rate and disease control rate of the observation group were higher than that of the control group. After treatment, tumor markers, vascular endothelial growth factors and inflammatory cytokines were lower than those in the control group. The quality of life score and peripheral lymphocyte subgroup were higher than the control group. The difference was statistically significant (P 0.05). Conclusions: Xiaoaiping combined with oxaliplatin and capecitabine is effective in the treatment of advanced metastatic gastric adenocarcinoma. It's worth popularizing.","PeriodicalId":348972,"journal":{"name":"Trends in Oncology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129526352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.37155/2717-5278-0301-4
Jack Korleski, H. Lopez-Bertoni
{"title":"PVSRIPO, A Potential New Tool in Our Fight against GBM","authors":"Jack Korleski, H. Lopez-Bertoni","doi":"10.37155/2717-5278-0301-4","DOIUrl":"https://doi.org/10.37155/2717-5278-0301-4","url":null,"abstract":"","PeriodicalId":348972,"journal":{"name":"Trends in Oncology","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130401318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.37155/2717-5278-2021-03-02-2
Lei Zhang, Zhiming Ma, S. Tian
{"title":"Gene Expression Profiles Reveal the Potential Link between Parkinson’s Disease and Gastric Cancer","authors":"Lei Zhang, Zhiming Ma, S. Tian","doi":"10.37155/2717-5278-2021-03-02-2","DOIUrl":"https://doi.org/10.37155/2717-5278-2021-03-02-2","url":null,"abstract":"","PeriodicalId":348972,"journal":{"name":"Trends in Oncology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131604834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.37155/2717-5278-0301-2
Ulana Kotowski, M. Faisal, Yan Ma, Inamaria Erovic, Boban M. Erovic
{"title":"Does Liquorice Root, Hawthorn Fruit and Chinese Plum Tea Improve Quality of Life in Head and Neck Cancer Patients after Primary or Adjuvant Radiotherapy? – A Randomized Double-blind Pilot Study","authors":"Ulana Kotowski, M. Faisal, Yan Ma, Inamaria Erovic, Boban M. Erovic","doi":"10.37155/2717-5278-0301-2","DOIUrl":"https://doi.org/10.37155/2717-5278-0301-2","url":null,"abstract":"","PeriodicalId":348972,"journal":{"name":"Trends in Oncology","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124193492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：